Messenger RNA (mRNA) has emerged as a promising therapeutic modality, but its inherent instability continues to limit its clinical applicability. To enhance stability and translational performance, we developed a non-enzymatic method for site-specific...
Messenger RNA (mRNA) has emerged as a promising therapeutic modality, but its inherent instability continues to limit its clinical applicability. To enhance stability and translational performance, we developed a non-enzymatic method for site-specific incorporation of chemically modified nucleotides at the 3′terminus of the poly(A) tail. Five imidazole-activated guanosine derivatives—L-GMP, IMP, 2′-O-Me-GMP, 2′-O-MOE-GMP, and 2′-F-GMP—were synthesized and incorporated into the poly(A) tail of luciferase mRNA through a guide RNA–mediated reaction. Gel electrophoresis and sequencing analyses confirmed successful incorporation, with IMP displaying the highest incorporation efficiency. In HEK293 cells, luciferase assays demonstrated enhanced translation for all modified mRNAs except the L-GMP–containing construct. Together, these findings indicate that chemical modification of the 3′poly(A) tail via non-enzymatic incorporation can improve mRNA stability and translation, highlighting its potential as a platform for next-generation mRNA therapeutics.